MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future

Authors

Wei Wang
Najah Albadari
Yi Du
Josef F Fowler
Hannah T Sang
Wa Xian
Frank McKeon
Wei Li
Jia Zhou
Ruiwen Zhang

Language

English

Publication Date

5-2-2024

Journal

Pharmacological Reviews

DOI

10.1124/pharmrev.123.001026

PMID

38697854

PMCID

PMC11068841

PubMedCentral® Posted Date

5-1-2024

PubMedCentral® Full Text Version

Post-print

Abstract

Since its discovery over 35 years ago, MDM2 has emerged as an attractive target for the development of cancer therapy. MDM2's activities extend from carcinogenesis to immunity to the response to various cancer therapies. Since the report of the first MDM2 inhibitor more than 30 years ago, various approaches to inhibit MDM2 have been attempted, with hundreds of small-molecule inhibitors evaluated in preclinical studies and numerous molecules tested in clinical trials. Although many MDM2 inhibitors and degraders have been evaluated in clinical trials, there is currently no Food and Drug Administration (FDA)-approved MDM2 inhibitor on the market. Nevertheless, there are several current clinical trials of promising agents that may overcome the past failures, including agents granted FDA orphan drug or fast-track status. We herein summarize the research efforts to discover and develop MDM2 inhibitors, focusing on those that induce MDM2 degradation and exert anticancer activity, regardless of the p53 status of the cancer. We also describe how preclinical and clinical investigations have moved toward combining MDM2 inhibitors with other agents, including immune checkpoint inhibitors. Finally, we discuss the current challenges and future directions to accelerate the clinical application of MDM2 inhibitors. In conclusion, targeting MDM2 remains a promising treatment approach, and targeting MDM2 for protein degradation represents a novel strategy to downregulate MDM2 without the side effects of the existing agents blocking p53-MDM2 binding. Additional preclinical and clinical investigations are needed to finally realize the full potential of MDM2 inhibition in treating cancer and other chronic diseases where MDM2 has been implicated.

Keywords

Humans, Proto-Oncogene Proteins c-mdm2, Neoplasms, Animals, Antineoplastic Agents, Molecular Targeted Therapy

Published Open-Access

yes

Recommended Citation

Wang, Wei; Albadari, Najah; Du, Yi; et al., "MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future" (2024). Faculty, Staff and Student Publications. 6704.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/6704